Rituximab-induced direct inhibition of T-cell activation

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma

Lorena Appio, Carlo Landoni, Maria La Targia et al. · Chemotherapy · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht, Nicolas Mounier, Devinder Gill et al. · Journal of Clinical Oncology · 2010 · 1.6K citations · Full text

Medicine, Oncology, Chemotherapy +13

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Kenneth R. Carson, Andrew M. Evens, Elizabeth Richey et al. · Blood · 2009 · 870 citations · Full text

Medicine, Immunology, Neurology +9